The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Palette Life Sciences sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Palette Life Sciences is a life sciences company that specializes in urology and urogynecology disorders, radiotherapy, colorectal conditions, and interventional oncology procedures. The company’s product portfolio includes Barrigel, a biodegradable injectable device for prostate rectum separation; Deflux, a minimally invasive first-line treatment for VUR (vesicoureteral reflux); Deflux for SUI (stress urinary incontinence); and Solesta, a minimally invasive first-line interventional treatment for fecal incontinence among others. Palette Life Sciences sells products in the US, Australia, Canada, Europe, Latin America, New Zealand, and Japan. Palette Life Sciences is headquartered in Stockholm, Sodermanland, Sweden. Key subsidiaries of Palette Life Sciences include Palette Life Sciences.
The key metrics of Palette Life Sciences related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Palette Life Sciences is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Palette Life Sciences.
For a detailed understanding of the performance of Palette Life Sciences, buy the report here.